CARLSMED Doubles Revenue, IPO Boosts Liquidity Amid Widening Losses

TL;DR

**CARLSMED's revenue surge is impressive, but widening losses mean the IPO cash infusion is a lifeline, not a victory lap – watch for sustained profitability.**

AI Summary

CARLSMED, INC. (CARL) reported a significant revenue increase for the three and six months ended June 30, 2025, with revenue doubling to $12.083 million from $6.081 million year-over-year for the quarter, and reaching $22.272 million for the six-month period, up from $11.167 million in 2024. Despite this growth, the company's net loss widened to $6.766 million for the quarter, compared to $6.277 million in the prior year, and to $12.495 million for the six months, up from $11.724 million. Operating expenses surged, with sales and marketing increasing to $7.869 million from $4.873 million for the quarter, and general and administrative expenses rising to $3.342 million from $2.010 million. The company completed an Initial Public Offering (IPO) on July 24, 2025, raising net proceeds of $93.5 million, which is not reflected in the June 30, 2025 financials. As of June 30, 2025, CARLSMED had $33.5 million in cash and cash equivalents and an accumulated deficit of $83.7 million, but expects the IPO proceeds to cover anticipated capital requirements for at least 12 months.

Why It Matters

CARLSMED's substantial revenue growth, doubling year-over-year, indicates strong market adoption for its aprevo Technology Platform, a positive signal for investors in the competitive surgical device sector. However, the widening net losses and increased operating expenses, particularly in sales and marketing, highlight the significant investment required for commercial expansion and product development. The successful $93.5 million IPO provides a critical liquidity injection, mitigating immediate going concern risks and offering a runway for continued operations and R&D, which is crucial for attracting and retaining top talent and securing market share against larger medical device companies. This financial stability could also reassure hospitals and surgeons about the long-term viability and support for the aprevo platform.

Risk Assessment

Risk Level: medium — CARLSMED reported an accumulated deficit of $83.7 million as of June 30, 2025, and expects to continue generating operating losses for the foreseeable future, indicating ongoing financial risk. While the $93.5 million net proceeds from the July 24, 2025 IPO provide a significant liquidity boost, the company's ability to achieve profitability and manage its cash burn rate remains a key concern, as evidenced by net cash used in operating activities of $15.197 million for the six months ended June 30, 2025.

Analyst Insight

Investors should monitor CARLSMED's upcoming earnings reports closely for signs of improved operating leverage and a narrowing net loss, as the IPO proceeds provide a temporary cushion. Focus on the company's ability to translate its strong revenue growth into reduced cash burn and a clear path to profitability, rather than just top-line expansion, before considering a long-term position.

Financial Highlights

debt To Equity

N/A

revenue

$12.083M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$6.766M

eps

N/A

gross Margin

N/A

cash Position

$33.5M

revenue Growth

+98.7%

Revenue Breakdown

Key Numbers

• $12.083M — Q2 2025 Revenue (Doubled from $6.081M in Q2 2024, indicating strong product adoption.)
• $22.272M — H1 2025 Revenue (Increased from $11.167M in H1 2024, showing consistent growth.)
• $6.766M — Q2 2025 Net Loss (Widened from $6.277M in Q2 2024, reflecting increased operating expenses.)
• $12.495M — H1 2025 Net Loss (Increased from $11.724M in H1 2024, despite revenue growth.)
• $93.5M — IPO Net Proceeds (Received on July 24, 2025, significantly boosting liquidity post-period end.)
• $83.7M — Accumulated Deficit (As of June 30, 2025, highlighting historical losses.)
• $33.5M — Cash and Cash Equivalents (As of June 30, 2025, prior to IPO proceeds.)
• $15.197M — Net Cash Used in Operating Activities (For the six months ended June 30, 2025, indicating ongoing cash burn.)
• 1-for-5.58 — Reverse Stock Split Ratio (Effectuated on July 10, 2025, impacting share counts retroactively.)
• 6,700,000 — Shares Offered in IPO (At $15.00 per share, completed on July 24, 2025.)

Key Players & Entities

• CARLSMED, INC. (company) — Registrant
• U.S. Food and Drug Administration (regulator) — Cleared aprevo interbody implants
• Customers Bank (company) — Lender for term loan
• Nasdaq Stock Market LLC (company) — Exchange where common stock is registered
• aprevo Technology Platform (product) — Company's primary product for spine fusion surgery
• $12.083 million (dollar_amount) — Revenue for three months ended June 30, 2025
• $93.5 million (dollar_amount) — Net proceeds from IPO on July 24, 2025
• $83.7 million (dollar_amount) — Accumulated deficit as of June 30, 2025
• $33.5 million (dollar_amount) — Cash and cash equivalents as of June 30, 2025
• $15.6 million (dollar_amount) — Debt outstanding under Customers Loan Agreement as of June 30, 2025

FAQ

Risk Factors

• Sustained Net Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $6.766 million for Q2 2025, widening from $6.277 million in Q2 2024. The accumulated deficit stood at $83.7 million as of June 30, 2025, indicating a history of unprofitability that could impact future operations and investor confidence.
• Significant Increase in Operating Expenses [medium — operational]: Sales and marketing expenses increased to $7.869 million in Q2 2025 from $4.873 million in Q2 2024, and G&A expenses rose to $3.342 million from $2.010 million. This surge in costs, outpacing revenue growth in percentage terms, contributes to the widening net loss.
• Dependence on Future Financing [high — financial]: While the IPO raised $93.5 million, the company had only $33.5 million in cash as of June 30, 2025. The company's ability to continue as a going concern relies on the effective deployment of these funds to cover anticipated capital requirements for at least 12 months.
• Post-IPO Market Performance [medium — market]: The IPO was completed on July 24, 2025, after the period end. The market's reception and sustained valuation of CARLSMED post-IPO will be critical. Any significant downturn in the stock price could affect future fundraising and investor sentiment.
• Reverse Stock Split Impact [low — operational]: A 1-for-5.58 reverse stock split was effectuated on July 10, 2025. While intended to increase the stock price, such splits can sometimes be perceived negatively by investors if not accompanied by fundamental business improvements.

Industry Context

CARLSMED operates in the medical technology sector, characterized by rapid innovation and significant R&D investment. The industry faces intense competition from established players and emerging startups, with a strong emphasis on regulatory approvals and market adoption of new devices and therapies.

Regulatory Implications

As a medical technology company, CARLSMED is subject to stringent regulatory oversight from bodies like the FDA. Compliance with evolving regulations, obtaining and maintaining necessary approvals, and managing potential recalls or adverse events are critical operational and financial risks.

What Investors Should Do

1. Monitor operating expense growth relative to revenue: While revenue is doubling, the widening net loss suggests expenses are growing faster. Investors should scrutinize the efficiency of sales and marketing spend.
2. Assess post-IPO cash burn rate: The $93.5 million IPO proceeds are expected to cover at least 12 months of operations. Investors should track the actual cash burn rate against projections.
3. Evaluate market reaction to the reverse stock split: Observe how the market interprets the 1-for-5.58 reverse stock split and its impact on share price and liquidity.
4. Analyze future revenue drivers: Understand the specific products or services contributing to the strong revenue growth and their sustainability.

Key Dates

• 2025-06-30: End of Second Quarter — Financials reported reflect performance up to this date, prior to IPO proceeds.
• 2025-07-10: Reverse Stock Split — A 1-for-5.58 reverse stock split was enacted, impacting share structure.
• 2025-07-24: Initial Public Offering (IPO) — Raised $93.5 million in net proceeds, significantly bolstering liquidity.

Glossary

Accumulated Deficit

The total net losses of a company since its inception that have not been offset by profits. (Indicates CARLSMED's historical unprofitability, standing at $83.7 million as of June 30, 2025.)

Reverse Stock Split

A corporate action to reduce the number of outstanding shares of stock, typically to increase the share price. (CARLSMED executed a 1-for-5.58 reverse split on July 10, 2025, affecting share count and price.)

Net Proceeds

The amount of money raised from an issuance of securities after deducting underwriting discounts and commissions, and other offering expenses. (CARLSMED raised $93.5 million in net proceeds from its IPO, crucial for future operations.)

Year-Over-Year Comparison

Compared to the prior year, CARLSMED has demonstrated impressive revenue growth, with Q2 revenue doubling to $12.083 million. However, this top-line expansion has been accompanied by a widening net loss, from $6.277 million to $6.766 million in Q2, due to significant increases in operating expenses, particularly in sales and marketing. No new material risks were highlighted in this filing compared to the general risks associated with a growth-stage medical technology company.

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value per share CARL The Nasdaq

Filing Documents

• carl-20250630.htm (10-Q) — 2526KB
• carl-ex10_6.htm (EX-10.6) — 267KB
• carl-ex10_7.htm (EX-10.7) — 122KB
• carl-ex31_1.htm (EX-31.1) — 17KB
• carl-ex31_2.htm (EX-31.2) — 17KB
• carl-ex32_1.htm (EX-32.1) — 10KB
• carl-ex32_2.htm (EX-32.2) — 10KB
• img165659793_0.jpg (GRAPHIC) — 7KB
• img166583314_0.jpg (GRAPHIC) — 7KB
• 0000950170-25-111953.txt ( ) — 9360KB
• carl-20250630.xsd (EX-101.SCH) — 993KB
• carl-20250630_htm.xml (XML) — 1623KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Balance Sheets as of June 30, 2025 and December 31, 2024 1 Condensed Statements of Operations and Comprehensive Loss for the Three and Six Months ended June 30, 2025 and 2024 2 Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit for the Three and Six Months Ended June 30, 2025 and 2024 3 Condensed Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 4 Notes to Condensed Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31 PART II. OTHER INFORMATION 31 Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 33

Signatures

Signatures 35 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements about: our ability to advance the aprevo Technology Platform and any potential future products through applicable regulatory approval processes; existing regulations and regulatory developments in the United States and other jurisdictions; our ability to maintain or improve our third-party payor reimbursement strategy; our ability to attract and retain hospitals and surgeons our expectations concerning orders for our products and utilization by existing hospitals and surgeons our expectations regarding the potential market size for the aprevo Technology Platform our ability to maintain our competitive technological advantages our intentions to pursue adjacent and international markets our ability to continue improving our products and technology; our commercialization and marketing capabilities and strategies; our ability to maintain or reduce our manufacturing times of our CMOs; our reliance on a limited number of CMOs; the implementation of our business model and strategic plans for our business and products and technology; our relationships with, and the capabilities of, our suppliers the sco

Financi al Statements

Item 1. Financi al Statements. CARLSMED, INC. CO NDENSED BALANCE SHEETS (in thousands, except for share and par value amounts) (unaudited) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 33,472 $ 40,125 Restricted cash 100 100 Accounts receivable, net of allowances of $ 1,576 and $ 1,239 , as of June 30, 2025 and December 31, 2024, respectively 9,711 6,766 Inventory 1,068 995 Prepaid expenses and other current assets 1,841 1,365 Total current assets 46,192 49,351 Property and equipment, net 972 260 Operating lease right-of-use assets 2,144 1,644 Other assets 3,962 569 Total assets $ 53,270 $ 51,824 Liabilities, Convertible Preferred Stock, and Stockholders' Deficit Current liabilities: Accounts payable $ 2,581 $ 2,412 Accrued liabilities 3,219 2,687 Accrued compensation 3,113 3,270 Short-term operating lease liabilities 571 449 Total current liabilities 9,484 8,818 Long-term portion of term loan, net 15,431 15,414 Long-term operating lease liabilities 1,705 1,317 Warrant liabilities 727 457 Other long-term liabilities 267 222 Total liabilities 27,614 26,228 Commitments and contingencies ( Note 9 ) Series A convertible preferred stock, $ 0.00001 par value; 4,902,814 shares authorized, issued, and outstanding, and $ 13,767 liquidation preference as of June 30, 2025 and December 31, 2024 13,578 13,578 Series B convertible preferred stock, $ 0.00001 par value; 4,393,481 shares authorized, 4,335,051 shares issued and outstanding, and $ 30,000 liquidation preference as of June 30, 2025 and December 31, 2024 29,801 29,801 Series C convertible preferred stock, $ 0.00001 par value; 6,028,243 and 4,910,500 shares authorized, 6,007,866 and 4,890,123 shares issued and outstanding, and $ 64,500 and $ 52,500 liquidation preference as of June 30, 2025 and December 31, 2024, respec

View Full Filing

View this 10-Q filing on SEC EDGAR